ResearcherGerman Cancer Research CenterNo recent work listed

Ahmed Murtaja

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5046363921. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper

Papers 2

The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis. Co-author DOI 10.3892/ol.2017.7526 ↗
Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. First author DOI 10.4161/cbt.29503 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hassan Adwan · 2 shared papers, 2014–2018 · strength 0.16
- Paper The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metast… DOI 10.3892/ol.2017.7526 ↗
- Paper Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. DOI 10.4161/cbt.29503 ↗
Martin Reinhold Berger · 2 shared papers, 2014–2018 · strength 0.16
- Paper The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metast… DOI 10.3892/ol.2017.7526 ↗
- Paper Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. DOI 10.4161/cbt.29503 ↗
Khamael K. Al-Taee · 1 shared paper, 2014 · strength 0.05
- Paper Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. DOI 10.4161/cbt.29503 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.